Helene F. S. Negaard
Papers
2
Total Citations
26
H-Index
2
About
Helene F. S. Negaard is a leading clinical researcher in urologic oncology, with a focused expertise in testicular cancer, particularly seminoma. Her major contributions center on redefining the standard of care for low-volume metastatic seminoma by championing primary retroperitoneal lymph node dissection (RPLND) as a viable, less-toxic alternative to traditional chemotherapy or radiotherapy. Her landmark 2024 study, drawing on the population-based Swedish Norwegian Testicular Cancer Group (SWENOTECA) cohort, demonstrated the oncological efficacy and surgical safety of RPLND for stage IIA–IIC disease, offering a pathway to avoid the long-term morbidity of cytotoxic treatments. This work, alongside her combined SWENOTECA and Cologne analysis (2023), has been instrumental in shifting clinical paradigms toward surgical management. With her most-cited paper accumulating 19 citations and her collaborative studies influencing international guidelines, Negaard’s research directly addresses the unmet need for reducing treatment-related toxicity while maintaining excellent survival outcomes. Her achievements place her at the forefront of testicular cancer surgery, making her a pivotal figure for students and researchers interested in evidence-based de-escalation of cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2